Merger Of Abarca And LucyRx May Not Be The Last PBM Deal This Year
Abarca Health and LucyRx, two independent pharmacy benefit management companies, have recently announced their decision to merge in response to the public’s increasing demand for better prescription drug prices. This merger aims to provide a viable alternative to the nation’s largest PBMs and create a modern, independent pharmacy benefit manager with the necessary scale, technology, and expertise to cater to commercial and government clients of all sizes.
The combined entity will serve over 9 million plan members across the United States, positioning it among the top 10 PBMs in terms of managed prescriptions. However, it will still be significantly smaller than the three dominant players in the market – CVS Health’s Caremark, Express Scripts (owned by Cigna), and OptumRx (owned by UnitedHealth Group) – which collectively control 80% of the market share.
PBMs play a crucial role in negotiating drug prices, managing prescription benefits, and acting as intermediaries between insurers, pharmacies, and drug manufacturers. The industry has come under increased scrutiny in recent years, with regulatory bodies investigating anticompetitive practices and pushing for greater transparency in pricing.
Smaller PBMs, such as Humana Pharmacy Solutions, MedImpact Healthcare Systems, and Prime Therapeutics, face challenges in coping with the rising administrative costs associated with regulatory compliance. The evolving regulatory landscape and growing demand for transparency are driving consolidation within the industry, with many smaller PBMs expected to either merge, be acquired, or cease operations in the coming years.
The executives at Abarca and LucyRx believe that the forces driving their merger will continue to reshape the PBM industry, prompting other players to seek strategic partnerships. The deal between the two companies will see them operate as individual subsidiaries of Healthcare Revolution Partners, maintaining their respective brands.
Jason Borschow, CEO of Abarca, emphasized the need for accountability and transparency in the market, stating that clients are demanding a higher level of service. David Blair, CEO of LucyRx, highlighted the shifting landscape of prescription care and the importance of operational scale in meeting the evolving demands of clients and patients.
The merger between Abarca and LucyRx represents a significant step towards creating a model for the future of the PBM industry. By combining their strengths and resources, the two companies aim to lead the way in delivering efficient and effective pharmacy benefit management services to their clients and patients. The deal is expected to close in the third quarter of this year, pending regulatory approvals, and will establish Healthcare Revolution Partners as a key player in the evolving healthcare market.
